PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/201512/31/2014
Total Revenue19,2429,1994,3643,523
Cost of Revenue15,2318,398730630
Gross Profit4,0118013,6342,893
Operating Expenses
Research Development28,05923,60819,02521,224
Selling General and Administrative12,30510,3568,27910,228
Non Recurring----
Others----
Total Operating Expenses55,59542,36228,03432,082
Operating Income or Loss-36,353-33,163-23,670-28,559
Income from Continuing Operations
Total Other Income/Expenses Net-48,9233,987-3,612-4,739
Earnings Before Interest and Taxes-36,353-33,163-23,670-28,559
Interest Expense-572-3,364-3,549-3,549
Income Before Tax-85,276-29,176-27,282-33,298
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-85,276-29,176-27,282-33,298
Non-recurring Events
Discontinued Operations--18985,3193,355
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-85,276-29,36558,037-29,943
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-85,276-29,36558,037-29,943